Moleculin Biotech, Inc. (MBRX) EPS Estimated At $-0.14

July 14, 2018 - By Lisa Delgado

Analysts expect Moleculin Biotech, Inc. (NASDAQ:MBRX) to report $-0.14 EPS on August, 13.They anticipate $0.07 EPS change or 100.00 % from last quarter’s $-0.07 EPS. After having $-0.11 EPS previously, Moleculin Biotech, Inc.’s analysts see 27.27 % EPS growth. The stock increased 1.16% or $0.02 during the last trading session, reaching $1.74. About 74,934 shares traded. Moleculin Biotech, Inc. (NASDAQ:MBRX) has risen 88.76% since July 14, 2017 and is uptrending. It has outperformed by 76.19% the S&P500.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. The company has market cap of $46.74 million. The Company’s lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. It currently has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma.

More notable recent Moleculin Biotech, Inc. (NASDAQ:MBRX) news were published by: Benzinga.com which released: “56 Biggest Movers From Yesterday” on June 22, 2018, also Benzinga.com with their article: “38 Stocks Moving In Wednesday’s Mid-Day Session” published on June 20, 2018, Benzinga.com published: “50 Biggest Movers From Yesterday” on June 21, 2018. More interesting news about Moleculin Biotech, Inc. (NASDAQ:MBRX) were released by: Investingnews.com and their article: “Pharmaceutical Update: Q2 2018 in Review” published on July 10, 2018 as well as Globenewswire.com‘s news article titled: “Moleculin Selected for the Russell Microcap Index” with publication date: June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.